Biotech Bulls & Breakthroughs

BioPharmCatalyst
  • 0,0 (0)
  • GELDANLAGE

Welcome to Biotech Bulls & Breakthroughs! This brand new podcast from BioPharmCatalyst explores the dynamic world of biotech investing alongside long-time biotech trader Sheff from Sheff Station. Each month, we will be discussing current events in the biotech industry and how these events impact investors, as well as a discussion of upcoming catalysts in the biotech space.

  1. 13. APR.

    The Future of Biomanufacturing | Michael Heltzen, eXoZymes

    In this episode of Biotech Bulls & Breakthroughs, John sits down with Michael Heltzen, CEO of exoZymes, to discuss the revolutionary move toward cell-free biomanufacturing. Discover how exoZymes is using AI to bypass the limitations of living cells, engineering "super-enzymes" through brute-force evolution, and bringing high-purity natural compounds like NCT to the mass market. eXoZymes Inc. https://www.biopharmcatalyst.com/company/EXOZ#/ 📲 Follow Michael Heltzen and eXoZymes: https://www.linkedin.com/in/michaelheltzen https://www.linkedin.com/company/exozymes https://exozymes.com/ In this episode: 🔹 Why "cell-free" systems outperform traditional cell fermentation. 🔹 How AI is used to "speed run" evolution for enzyme development 🔹 Insights into the 2024 exoZymes IPO and their commercial roadmap. 🧭 Track upcoming catalysts: https://www.biopharmcatalyst.com/calendars/fda-calendar 🎧 Listen to more episodes: https://www.biopharmcatalyst.com/podcast 📈 See Sheff’s Watchlist: https://www.biopharmcatalyst.com/sheffs-trades 📲 Follow BioPharmCatalyst: https://x.com/BPharmCatalyst 📲 Follow Sheff: https://x.com/SheffStation Disclaimer: BioPharmCatalyst is not a registered investment advisory firm and the views on this podcast are not to intended to be financial advice. The stocks discussed in this podcast may be held in personal or other investment accounts. This content is for informational purposes only and should not be considered investment advice. Always do your own research before making any investment decisions.

    32 Min.

  2. 25. MÄRZ

    Biotech Investing: FDA One Pivotal Trial and 2Q Outlook | Biotech Bulls & Breakthroughs

    In this episode, as the biotech earnings season continues, John Gagliano and Sheff Sheffield dive deep into the new FDA one pivotal trial as an alternative to the regulatory pathway, and what it means for trial timelines and company runways in 2026. If you're trading biotech, understanding these structural shifts is no longer optional—it's a matter of survival. https://www.nejm.org/doi/full/10.1056/NEJMsb2517623 In this episode: 🔹 FDA updates on new pathways are changing the game. 🔹 Why a 12-month runway is the new "red line" for investors 🔹 Sheff's Watchlist for the following quarter 🧭 Track upcoming catalysts: https://www.biopharmcatalyst.com/calendars/fda-calendar 🎧 Listen to more episodes: https://www.biopharmcatalyst.com/podcast 📈 See Sheff’s Watchlist: https://www.biopharmcatalyst.com/sheffs-trades 📲 Follow BioPharmCatalyst: https://x.com/BPharmCatalyst 📲 Follow Sheff: https://x.com/SheffStation Disclaimer: BioPharmCatalyst is not a registered investment advisory firm and the views on this podcast are not to intended to be financial advice. The stocks discussed in this podcast may be held in personal or other investment accounts. This content is for informational purposes only and should not be considered investment advice. Always do your own research before making any investment decisions.

    38 Min.

  3. 10. MÄRZ

    Tackling Rare Genetic Diseases with Diagonal Therapeutics

    In this episode, John Gagliano speaks with Eric Duhaime, Senior VP of Finance and Corporate Development at Diagonal Therapeutics, about the innovative approaches the company is taking in drug development, with a particular focus on clustering agonist antibodies and rare genetic diseases. Eric shares his journey in biotech, the mission of Diagonal Therapeutics, and insights into the current biotech market trends. The conversation also covers the company's pipeline, their strategic use of health data to prove commercial viability, and their novel bispecific antibodies, highlighting the importance of tackling the root causes of diseases like Hereditary Hemorrhagic Telangiectasia (HHT). 📲 Follow Eric Duhaime in Diagonal Therapeutics: https://www.linkedin.com/company/diagonal-therapeutics https://diagonaltx.com/ In this episode: 🔹 Novel antibodies for rare diseases. 🔹 Restoring normal intracellular signaling pathways. 🔹 Navigating the current biotech market. 🧭 Track upcoming catalysts: https://www.biopharmcatalyst.com/calendars/fda-calendar 🎧 Listen to more episodes: https://www.biopharmcatalyst.com/podcast 📈 See Sheff’s Watchlist: https://www.biopharmcatalyst.com/sheffs-trades 📲 Follow BioPharmCatalyst: https://x.com/BPharmCatalyst 📲 Follow Sheff: https://x.com/SheffStation Disclaimer: BioPharmCatalyst is not a registered investment advisory firm and the views on this podcast are not to intended to be financial advice. The stocks discussed in this podcast may be held in personal or other investment accounts. This content is for informational purposes only and should not be considered investment advice. Always do your own research before making any investment decisions.

    20 Min.

  4. 21. FEB.

    Talking Biotech: Biotech Stocks to Watch, Hedge Funds & More

    In this episode, as the biotech earnings season continues, John Gagliano and Sheff Sheffield explore the importance of cash burn in biotech, the role of hedge funds, and the many catalysts expected by the end of the quarter. In this episode: 🔹 The importance of Cash in biotech. 🔹 How hedge funds' 13-F filings influence biotech stocks. 🔹 Companies relocating production to the US. 🧭 Track upcoming catalysts: https://www.biopharmcatalyst.com/calendars/fda-calendar 🎧 Listen to more episodes: https://www.biopharmcatalyst.com/podcast 📈 See Sheff’s Watchlist: https://www.biopharmcatalyst.com/sheffs-trades 📲 Follow BioPharmCatalyst: https://x.com/BPharmCatalyst 📲 Follow Sheff: https://x.com/SheffStation Disclaimer: BioPharmCatalyst is not a registered investment advisory firm and the views on this podcast are not to intended to be financial advice. The stocks discussed in this podcast may be held in personal or other investment accounts. This content is for informational purposes only and should not be considered investment advice. Always do your own research before making any investment decisions.

    1 Std. 15 Min.

  5. 22. JAN.

    Navigating the Future of Biotech: Insights from the JP Morgan Healthcare Conference 2026

    In this episode, as the biotech landscape continues to evolve, the recent JP Morgan Healthcare Conference 2026 has set the stage for an exciting year ahead. John Gagliano and Sheff Sheffield delve into the key takeaways from the conference, exploring significant acquisitions, emerging trends, and the role of artificial intelligence in shaping the industry's future.  In this episode: 🔹 Growth areas in immunology, metabolism, neurology, and oncology will drive the industry forward in 2026. 🔹 China’s growing role in the market necessitates collaboration with U.S. companies for enhanced innovation.   🔹 AI is becoming a transformative force in biotech, expediting drug discovery and product development.    Sheff is proud to support the Northwest Association for Blind Athletes. Join us in empowering life-changing opportunities for visually impaired youth and adults through sports and community engagement. You can support this as well in the link below: Support NWABA: https://nwaba.org/support/other-ways-to-help/sheffstation/#join-sheff-station 🧭 Track upcoming catalysts: https://www.biopharmcatalyst.com/calendars/fda-calendar 🎧 Listen to more episodes: https://www.biopharmcatalyst.com/podcast 📈 See Sheff’s Watchlist: https://www.biopharmcatalyst.com/sheffs-trades 📲 Follow BioPharmCatalyst: https://x.com/BPharmCatalyst 📲 Follow Sheff: https://x.com/SheffStation Disclaimer: BioPharmCatalyst is not a registered investment advisory firm and the views on this podcast are not to intended to be financial advice. The stocks discussed in this podcast may be held in personal or other investment accounts. This content is for informational purposes only and should not be considered investment advice. Always do your own research before making any investment decisions.

    50 Min.

  6. 11.12.2025

    2025 Biotech Recap & Set Up For 2026

    In this episode, John Gagliano and Chef Sheffield review the biotech landscape of 2025, discussing key trends, FDA clarity, and the impact of CRLs on investor confidence. They highlight significant companies and catalysts to watch as they transition into 2026, emphasizing the importance of institutional investments and upcoming events that could shape the market.  In this episode: 🔹 2025 saw increased clarity from the FDA 🔹 The upcoming JP Morgan conference will set the stage for 2026 🔹 CRLs are not the end 🧭 Track upcoming catalysts: https://www.biopharmcatalyst.com/calendars/fda-calendar 🎧 Listen to more episodes: https://www.biopharmcatalyst.com/podcast 📈 See Sheff’s Watchlist: https://www.biopharmcatalyst.com/sheffs-trades 📲 Follow BioPharmCatalyst: https://x.com/BPharmCatalyst 📲 Follow Sheff: https://x.com/SheffStation Disclaimer: BioPharmCatalyst is not a registered investment advisory firm and the views on this podcast are not to intended to be financial advice. The stocks discussed in this podcast may be held in personal or other investment accounts. This content is for informational purposes only and should not be considered investment advice. Always do your own research before making any investment decisions.

    48 Min.

  7. 30.10.2025

    Understanding Catalysts in Biotech Trading

    In this episode, John Gagliano and Sheff Sheffield discuss the current state of the biotech market as they approach the end of the year. They reflect on recent trading successes and challenges, emphasizing the importance of understanding catalysts and market reactions. The conversation also highlights the significance of insider trading and institutional movements in stock performance. Finally, they explore upcoming catalysts and provide insights into their stock watchlist for the remainder of the year. In this conversation, CS (Sheff) Sheffield discusses various emerging biotech companies and their upcoming clinical trials, data releases, and market implications. He highlights the significance of low float stocks, the potential for substantial market movements based on positive data, and the importance of regulatory pathways in the biotech industry. The discussion also covers specific companies, their innovative therapies, and the competitive landscape in the pharmaceutical market, particularly focusing on PDUFA dates and biosimilars. In this episode: 🔹 Institutional buying can greatly influence stock prices.  🔹 Low float stocks can lead to significant price movements.  🔹 Patience is crucial when waiting for 510k approvals.  Sheff is proud to support the Northwest Association for Blind Athletes. Join us in empowering life-changing opportunities for visually impaired youth and adults through sports and community engagement. You can support this as well in the link below: Support NWABA: https://nwaba.org/support/other-ways-to-help/sheffstation/#join-sheff-station 🧭 Track upcoming catalysts: https://www.biopharmcatalyst.com/calendars/fda-calendar 🎧 Listen to more episodes: https://www.biopharmcatalyst.com/podcast 📈 See Sheff’s Watchlist: https://www.biopharmcatalyst.com/sheffs-trades 📲 Follow BioPharmCatalyst: https://x.com/BPharmCatalyst 📲 Follow Sheff: https://x.com/SheffStation Disclaimer: BioPharmCatalyst is not a registered investment advisory firm and the views on this podcast are not to intended to be financial advice. The stocks discussed in this podcast may be held in personal or other investment accounts. This content is for informational purposes only and should not be considered investment advice. Always do your own research before making any investment decisions.

    50 Min.

  8. 07.10.2025

    Innovations in Biotech: A Deep Dive with MoMA Therapeutics

    In this episode, John Gagliano speaks with Neil Lineberry, VP of Corporate Development at MoMA Therapeutics, about the innovative approaches the company is taking in drug development, with a particular focus on dynamic proteins and precision medicine. Neil shares his journey in biotech, the mission of MoMA Therapeutics, and insights into the current biotech market trends. The conversation also covers the company's pipeline, collaborations, and the Nomatic platform, highlighting the importance of tailoring the rapies to individual patient needs. 📲 Follow Neil Lineberry:  https://www.linkedin.com/in/neil-lineberry-wahoo https://momatx.com/team/ In this episode: 🔹 Precision medicine tailors therapy to the patient's unique characteristics. 🔹 MoMA's lead program targets DNA polymerase theta for cancer treatment 🔹 Upcoming data readouts are critical for MoMA's future growth. 🧭 Track upcoming catalysts: https://www.biopharmcatalyst.com/calendars/fda-calendar 🎧 Listen to more episodes: https://www.biopharmcatalyst.com/podcast 📈 See Sheff’s Watchlist: https://www.biopharmcatalyst.com/sheffs-trades 📲 Follow BioPharmCatalyst: https://x.com/BPharmCatalyst 📲 Follow Sheff: https://x.com/SheffStation Disclaimer: BioPharmCatalyst is not a registered investment advisory firm and the views on this podcast are not to intended to be financial advice. The stocks discussed in this podcast may be held in personal or other investment accounts. This content is for informational purposes only and should not be considered investment advice. Always do your own research before making any investment decisions.

    30 Min.
Alle anzeigen (16)

Info

Welcome to Biotech Bulls & Breakthroughs! This brand new podcast from BioPharmCatalyst explores the dynamic world of biotech investing alongside long-time biotech trader Sheff from Sheff Station. Each month, we will be discussing current events in the biotech industry and how these events impact investors, as well as a discussion of upcoming catalysts in the biotech space.

Informationen

  • Erstellt von
    BioPharmCatalyst
  • Jahre aktiv
    2025 - 2026
  • Folgen
    16
  • Bewertung
    Unbedenklich
  • Copyright
    © 2026 Biotech Bulls & Breakthroughs
  • Sendungswebsite
    Biotech Bulls & Breakthroughs
  • Anbieter

Das gefällt dir vielleicht auch